Impel Pharmaceuticals Inc.
IMPL · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $0 | $15 | $35 | $61 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $7 | $7 | $6 | $7 |
| Inventory | $7 | $7 | $8 | $8 |
| Other Curr. Assets | $10 | $4 | $2 | $3 |
| Total Curr. Assets | $23 | $33 | $52 | $80 |
| Property Plant & Equip (Net) | $8 | $8 | $9 | $7 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $4 | $4 | $4 | $2 |
| Total NC Assets | $12 | $12 | $13 | $9 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $35 | $45 | $65 | $89 |
| Liabilities | – | – | – | – |
| Payables | $4 | $3 | $6 | $6 |
| Short-Term Debt | $113 | $50 | $2 | $2 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $8 | $68 | $14 | $15 |
| Total Curr. Liab. | $125 | $121 | $22 | $22 |
| LT Debt | $2 | $3 | $51 | $50 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $64 | $61 |
| Total NC Liab. | $2 | $3 | $115 | $111 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $127 | $124 | $138 | $133 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$372 | -$359 | -$351 | -$321 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $280 | $279 | $278 | $277 |
| Total Equity | -$92 | -$79 | -$73 | -$44 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $35 | $45 | $65 | $89 |
| Net Debt | $115 | $37 | $17 | -$9 |